Acne Vulgaris

Healio has compiled June’s most-read news in dermatology.

Rehmannia glutinosa leaf extract supplementation improved acne severity, skin hydration and the quality of life of women with acne vulgaris, according to a study.

Trifarotene cream 0.005%, in conjunction with a proper skincare regimen, reduced acne lesions and acne-induced hyperpigmentation within 24 weeks, according to study.

High adherence to an antioxidant diet reduced the risk for acne impacting patient quality of life in women, according to a study.

The American Academy of Dermatology has released new care guidelines for acne vulgaris, according to a press release.

Researchers found that the efficacy of clascoterone cream 1% for the treatment of acne vulgaris increased over time up to 12 months and thus recommend persistent treatment regimens for optimal results, according to a study.

The FDA’s approval of IDP-126 was the most read Healio acne story this year, followed by coverage of a study finding IDP-126 improves patients’ quality of life compared to vehicle. News regarding the efficacy of M-PDT and clascoterone cream, as well as an update to the FDA’s iPledge recommendations, rounded out 2023’s important acne updates.

Higher acne vulgaris prevalence was associated with puberty status, skin of color and weight gain among adolescents, according to a study.

Newly FDA-approved IDP-126 gel improved quality of life outcomes in patients with acne vulgaris over vehicle, according to a study.

The FDA has approved IDP-126 for the treatment of acne in patients aged 12 years and older, Bausch Health announced in a press release.